MINNEAPOLIS, Dec. 7, 2011 /PRNewswire/ -- Uroplasty, Inc.
(NASDAQ: UPI), a medical device company that develops, manufactures
and markets innovative proprietary products to treat voiding
dysfunctions, announced today that David
Kaysen, President and CEO, and Medi
Jiwani, Vice President and CFO, will present the Company's
business strategy and financial results at the Oppenheimer 22nd
Annual Healthcare Conference at 2:10 PM
ET on Tuesday, December 13,
2011 at The Waldorf Astoria Hotel in New York.
Attendance at the conference is by invitation only. A live
audio webcast of the presentation will be broadcast via the
Internet. Those interested in listening to the webcast may
access it at
http://www.veracast.com/webcasts/opco/healthcare2011/90116388.cfm
or through Uroplasty's website at www.uroplasty.com. An archived
replay of the presentation will be available for 90 days.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned
subsidiaries in The Netherlands
and the United Kingdom, is a
medical device company that develops, manufactures and markets
innovative proprietary products for the treatment of voiding
dysfunctions. Our focus is the continued commercialization of our
Urgent® PC Neuromodulation System, the only FDA-cleared
neuromodulation system that delivers posterior tibial nerve
stimulation (PTNS) for the office-based treatment of overactive
bladder and associated symptoms of urgency, frequency and urge
incontinence. We also offer Macroplastique® Implants, an injectable
urethral bulking agent for the treatment of adult female stress
urinary incontinence primarily due to intrinsic sphincter
deficiency. For more information on the company and its products,
please visit Uroplasty, Inc. at www.uroplasty.com.
For Further
Information:
Uroplasty, Inc.
David Kaysen, President and
CEO, or
Medi Jiwani, Vice
President, CFO, Treasurer
952.426.6140
|
EVC Group
Doug Sherk/Jenifer Kirtland
(Investors), 415.568.9349
Chris Gale (Media),
646.201.5431
|
SOURCE Uroplasty, Inc.